Haemophilia

Article	Citations
Utilization and optimization of an electronic self‐administered bleeding assessment tool (E‐Self BAT) for the screening of pediatric bleeding disorders in the hematology clinic	73
Cross‐sectional study evaluating the association of haemophilia‐related distress and clinically relevant outcomes	48
Deciphering a novel complex inversion affecting F8 in a family with severe haemophilia A by optical genome mapping	47
Issue Information	47
AUTHOR INDEX	37
Diminished cortical bone density of long bones among children with haemophilic arthropathy	34
	32
American Thrombosis and Hemostasis Network: National Bleeding Disorders Foundation Data Commons: Better Together	26
Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab	26
COMMITTEE LIST	25
Arthroscopic ankle surgery in people with haemophilia	25
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays	24
Preoperative bleeding risk assessment with ISTH‐BAT and laboratory tests in patients undergoing elective surgery: A prospective cohort study	24
Safety and efficacy of a self‐induced myofascial release protocol using a foam roller in patients with haemophilic knee arthropathy	24
AUTHOR INDEX	23
Exploring a potential role for selective COX‐2 inhibitors for the prevention of hemophilic arthropathy	23
Committee List	22
Assessing the factors affecting the accessibility of primary dental care for people with haemophilia	21
Modulation of Haemostatic Balance in Combined von Willebrand Disease and Antithrombin Deficiency: A Comprehensive Family Study	20
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors	20
Giving Choice a Voice: Commentary on Development of the World Federation of Hemophilia Shared Decision‐Making Tool	20
Cross‐Cultural Translation of the Adolescent Menstrual Bleeding Questionnaire (AMBQ)	20
	19
Issue Information	19
Clinical outcomes after joint surgery in patients on turoctocog alfa pegol (N8‐GP) prophylaxis: A post hoc analysis	18

Reliability of the submaximal iSTEP performance test in children with haemophilia	17
Prostate biopsy and prostate cancer management in patients with haemophilia: The experience of French Haemophilia Treatment Centres	16
Gaining more insight into ankle pain in haemophilia: A study exploring pain, structural and functional evaluation of the ankle joint	16
Issue Information	16
Speaker Abstracts	16
	16
AHP Oral Abstracts	16
	15
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound	15
Late Breaking Abstracts	15
Comparative analysis of the pivotal studies of extended half‐life recombinant FVIII products for treatment of haemophilia A	15
A distinct common p.Gln317* mutation among causative LMAN1 genetic mutations of combined factor V and factor VIII deficiency in five Taiwanese families	15
A systematic review and narrative synthesis of footwear and orthotic devices used in the management of ankle haemarthrosis and haemarthropathy in haemophilia	14
Intracranial haemorrhage among a population of haemophilic patients in Nepal: Challenges and future direction	14
The actual and ideal roles of haemophilia treatment centre social workers in the United States and the barriers to ideal roles	14
Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?	14
Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay	14
Altered brain activity and functional networks in school‐age boys with severe haemophilia A: A resting‐state functional magnetic resonance imaging study	14
Haemophilia B in Algeria: Realities and therapeutic perspectives	14
Issue Information	14
Issue Information	14
Rare bleeding disorders: Advances in management	13
A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV?	13
Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor	13
Acquired haemophilia A: A 15‐year population‐based review of incidence rate, patient demographics and treatment outcomes	13
Riding the wave of change: Providing solid ground to support nursing with patient transitions to novel haemophilia therapies	13
Haemophilia B, severe childhood obesity and other extra‐haematological features associated with similar 4Mb‐deletions on Xq27: Clinical findings, molecular insights and literature update	13
Benefits of physical activity self‐monitoring in patients with haemophilia: a prospective study with one‐year follow‐up	13
Health‐related quality of life among adults with haemophilia in China: A comparison with age‐matched general population	13
Bridging the gap: Survey highlights challenges and solutions in outreach and identification of people with inherited bleeding disorders	13
	13
The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti‐FVIII antibody	12
ABSTRACT BOOK OF 12th BIC International Conference	12
Diagnosis of rare bleeding disorders	12
Desmopressin (DDAVP) use in patients with von Willebrand disease: A single‐centre retrospective review of test response and clinical outcomes	12
Effect of lower VWF and FXI levels on levonorgestrel IUS and endometrial ablation treatment success in heavy menstrual bleeding: An exploratory study	12
Radiosynovectomy in haemophilic synovitis and arthropathy of the knee: A scoping review	12
The detrimental effects of iron to the joint; aggravation by inflammation	12
Issue Information	12
Issue Information	12
Issue Information	12
	12
Dental habits and oral health in children and adolescents with bleeding disorders: A single‐institution cross‐sectional study	11
Into a brave new world: Haemophilia A & von Willebrand Disease Surgery with novel therapies	11
Prevalence of Bleeding Symptoms in Denmark Using the Patient‐administered Bleeding Assessment Tool (self‐BAT)	11
Psychophysical assessment of pain in adults with moderate and severe haemophilia: A cross‐sectional study	11
Increased acute care utilisation, comorbidities and mortality in adults with haemophilia: A population‐based cohort study from 2012 to 2019	11
Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates	11
18F‐FDG PET/CT imaging for haemophilic arthropathy compared with clinical, radiological and power Doppler sonographic characteristics of 20 haemophilia patients	11
Changes in pain profile of patients with haemophilia during 1‐year follow‐up	11

Haemophilia gene therapy—Update on new country initiatives	11
Recommendations for Psychosocial Support during Gene Therapy: Results From an EAHAD Interdisciplinary Roundtable	10
Occupational therapy in the management of haemophilia patients: A scoping review	10
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies	10
The legacy of haemophilia: Memories and reflections from three survivors	10
Design, development and usability of an educational AI chatbot for People with Haemophilia in Senegal	10
Administration of gene therapy for haemophilia – The hub and spoke model and its regional differences and challenges	10
Big picture initiatives in bleeding disorders	10
Promoting physical activity for people with haemophilia in the age of new treatments	10
Clinical features and genetic defect in six index patients with congenital fibrinogen disorders: Three novel mutations with one common mutation in Taiwan's population	10
Measuring anxiety and depression in young adult men with haemophilia using PROMIS	10
Total joint arthroplasty in the patients with haemophilia: General or neuraxial anaesthesia?	10
Physiological correction of hereditary mild hypofibrinogenemia during pregnancy	10
Impact of COVID‐19 on professionals and patients in haemophilia care – The perspective from the EAHAD Psychosocial Working Group	10
Evaluation of one‐stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion	9
On the Price of Valoctogene Roxaparvovec in Germany and Italy	9
Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences	9
Age‐specific incidence of joint disease in paediatric patients with haemophilia: A single‐centre real‐world outcome based on consecutive US examination	9
Emicizumab plasma levels after accelerated saturation in acquired haemophilia A	9
Bone mineral density in haemophilia – a multicentre study evaluating the impact of different replacement regimens	9
Screening for subclinical synovial proliferation in haemophilia: A systematic review and meta‐analysis comparing physical examination and ultrasound	9
Impact of obesity on factor VIII and von Willebrand factor levels in patients with Type 1 von Willebrand disease and low von Willebrand factor: An analysis of the ATHNdataset	9
Driving improvement of diagnosis and awareness of heavy menstrual bleeding in women among physicians	9
Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries–Comparisons to Matched Controls	9
Sexual functioning in men with haemophilia: Data from the haemophilia in the Netherlands‐6 study	9
Peri‐operative desmopressin combined with pharmacokinetic‐guided factor VIII concentrate in non‐severe haemophilia A patients	9
A post hoc comparative real‐world analysis of HEAD‐US score for joint health assessment of patients with severe haemophilia A and B in Spain	9
Health‐related quality of life of Indonesian children with hemophilia	8
We need better health‐related quality‐of‐life data for children with haemophilia in lower‐income countries	8
Blood pressure in persons with haemophilia with a focus on haemophilia‐specific risk factors	8
Methods for anti‐factor VIII antibody levels in haemophilia A patients – validation of a multiplex immunoassay and comparability with assays measuring non‐neutralising and neutralising antibodies (inh	8
Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis	8
The importance and evolution of bleeding disorder registries	8
	8
	8
EAHAD haemophilia gene therapy clinical outcome database (EAHAD‐GTD)	8
Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics	8
Evaluating the impact of the self‐BAT screening tool on patient outcomes: Results of the let's talk period project	8
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view	8
Low immunogenicity of emicizumab in persons with haemophilia A	8
Factor X inhibitors: A seldom seen but important antibody mediated process	8
Prevalence of comorbid conditions among older males with haemophilia receiving care in haemophilia treatment centers in the United States	8
Synovitis and joint health in patients with haemophilia: Statements from a European e‐Delphi consensus study	8
Screening for inattention, hyperactivity and impulsivity in children with haemophilia: A quality improvement intervention	8
Impact of inherited bleeding disorders on maternal bleeding and other pregnancy outcomes: A population‐based cohort study	8
Demographics, clinical profile and treatment landscape of patients with haemophilia B in China	8
The World Health Organisation's list of essential medicines and haemophilia treatment products	8
Is it time for patient involvement in Haemophilia?	8
Humanistic burden of problem joints for children and adults with haemophilia	8
Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A	7
Treatment of thrombotic cardiovascular diseases in people with haemophilia: A Japanese consensus study	7
Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India	7
Validity of the four‐square step test in persons with haemophilia	7
Direct transfer of data of people with haemophilia from the Thai Haemophilia Treatment Centre Registry to the World Bleeding Disorders Registry of the World Federation of Hemophilia	7
Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States	7
Identifying hemophilia B carriers: Utility of aPTT, factor IX levels and ratios of factor IX to other Vitamin K dependent factors	7
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal	7
Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model	7
CCS_Book of abstracts	7
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update	7
Nurse‐led education of people with bleeding disorders and their caregivers: A scoping review	7
Functional clinical motor performance tests to assess potential fall risks in patients with haemophilia: A case‐control study	7
Therapeutic and technological advancements in haemophilia care: Quantum leaps forward	7
Real‐world data on emicizumab prophylaxis in the Milan cohort	7
Clinical and Economic Burden of Patients with Haemophilia A and B in France: Analysis of a Nationwide Claims Database	7
Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single‐centre study	7
Towards novel treatment options in von Willebrand disease	7
Clinical, economic, and health‐related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviews	7
Efficacy and Safety of Aspiration and Intra‐Articular Injection of Tranexamic Acid in Acute Knee Hemarthrosis of Adult Haemophilic Patients: A Randomized Clinical Trial Study	7
Successful treatment of COVID‐19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit	7
Voices of patients with hemophilia: Life‐changing gene therapy	7
The humanistic and economic burden of problem joints for children and adults with moderate or severe haemophilia A: Analysis of the CHESS population studies	7
Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review	7
Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset	7
Trends in prescribing practices for management of haemophilia: 1999–2021	7
Effectiveness of therapeutic exercise and cognitive‐behavioural therapy combined protocol on functionality, pain and joint health in people with haemophilia: Secondary analysis of a controlled trial	7
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies	7
Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring	7
Abstracts	7
Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China	7

Development of a Single‐Tube Reverse Transcription Real‐Time PCR Assay for Diagnosis of F8 Intron 22 Inversion in Patients and Carriers of Haemophilia A	7
Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies	7
Post‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A	6
Issue Information	6
Issue Information	6
Issue Information	6
Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series	6
PUBLICATION ONLY ABSTRACTS	6
	6
Racial and ethnic differences in reported haemophilia death rates in the United States	6
Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A	6
The results of a survey about psychosocial care throughout Europe	6
Which part of the blood in the knee joint is responsible for its detrimental effects? (An experimental study on the knee joint in rabbits)	6
A cross‐sectional follow‐up study of physical activity in adults with moderate and severe haemophilia	6
	6
A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiative	6
Low vitamin C status and hypermobility‐related disorders in patients with bleeding disorder of unknown cause	6
von Willebrand disease (VWD) and BATs: How do they connect and why should I care?	6
Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A	6
Long‐term follow‐up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma‐derived factor VIII (Koate) that contains ADAMTS13	6
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors	6
Real world management of individuals with severe FXI deficiency and its impact on clinical outcomes: Experience from a haemophilia treatment centre	6
Mental health disorders and health‐related quality of life in adults with inherited bleeding disorders in central South Africa	6
Nephrotic syndrome in two haemophilia B children with inhibitor under low‐dose immune tolerance induction combined with rituximab‐based immunosuppressant protocol	6
Gene therapy – are we ready now?	6
Low‐dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success	6
High Prevalence of Platelet Function Disorders in Women Referred for Surgical Management of Refractory Heavy Menstrual Bleeding	6
Preclinical development and characterization of a human plasma‐derived high‐purity factor X concentrate for therapeutic use	6
Landmark endorsement of a global registry: The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), publicly endorses World Federation of Hemophilia Gene Therapy Regi	6
Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study	6
Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy	5
The effects of time and temperature on the in vitro stability of emicizumab in blood samples: Implications for laboratory and clinical practices	5
The impact of obesity on chronic pain in patients with haemophilia: A multicentre retrospective analysis	5
Dentistry for patients with haemophilia: Trialling a safe and economical change in management	5
	5
Validation of the patients‐specific functional scale in patients with haemophilia	5
SPEAKER ABSTRACTS	5
In response to WFH guidelines for the management of haemophilia, 3rd edition: Is there a difference between extended‐half‐life FVIII products or not?	5
Adult haematology clinics for menstruating/pregnant patients: A single center experience and lessons learned	5
Knowledge gaps in health‐related quality of life research performed in children with bleeding disorders – A scoping review	5
Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII‐free emicizumab therapy	5
A national assessment of standards of care for inherited bleeding disorders in Canada	5
Issue Information	5
	5
Issue Information	5
A decreased and less sustained response to surrogates of haemostatic stress correlates with bleeding in type 1 von Willebrand disease	5
Issue Information	5
Use of electronic self‐administered bleeding assessment tool in diagnosis of paediatric bleeding disorders	5
Issue Information	5
Joint bleeds in mild hemophilia: Prevalence and clinical characteristics	5
Reply to: Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?	5
A full molecular picture of F8 intron 1 inversion created with optical genome mapping	5
Methylome analysis for haemophilia A intron 22 inversion patients with and without inhibitors: A pilot study	5
Reinvestigation of unidentified causative variants in FXI‐deficient patients: Focus on gene segment deletions	5
Sixth Åland Island Conference on von Willebrand disease	5
An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency	5
Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis	4
How good does ChatGPT answer frequently asked questions about haemophilia?	4
Initial von Willebrand factor antigen values in adolescent females predict future values	4
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience	4
Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study	4
Recurrence of a high‐titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis	4
Corrigendum	4
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis	4
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy	4
Effects of a supervised therapeutic exercise program on musculoskeletal health and gait in patients with haemophilia: A pilot study	4
Risk factors, treatment and survival rates of late‐onset acquired haemophilia A: A cohort study from the Shizuoka Kokuho Database	4
Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency	4
The effect of age on the pressure pain threshold of asymptomatic ankles and knees in young individuals with haemophilia	4
Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items	4
Physical activity in Norwegian teenagers and young adults with haemophilia A compared to general population peers	4
Functional decline in persons with haemophilia and factors associated with deterioration	4
What can we expect for adolescents and adults with haemophilia switched to low‐dose prophylaxis from episodic treatment for over 3 years? A real‐world snapshot in China	4
The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A	4
Quantitative measurements of haemophilic joint tissues by point‐of‐care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters	4
Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease	4
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective	4
Ligneous conjunctivitis and use of human plasminogen eyedrops: The Italian experience	4
Prevalence of COVID‐19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: A survey from Europe	4
Risk factors for increased perioperative blood loss during total knee arthroplasty in patients with haemophilia	4
Physical activity and factor VIII levels in patients with haemophilia: A real‐world prospective observational study	4
Commentary on Laffan et al expert consensus for equitable care for VWD	4
Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022	4
Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature	4
Main Congress Oral Abstracts	4
Haemophilic arthropathy: Contemporary management challenges and a future scenario	4
	4
On‐demand treatment with the iron chelator deferasirox is ineffective in preventing blood‐induced joint damage in haemophilic mice	4
Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy	4
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey	4
Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries	4
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study	4
A review of the pharmacokinetics, efficacy and safety of high‐purity factor X for the prophylactic treatment of hereditary factor X deficiency	4
Patient‐derived assessment tool using musculoskeletal ultrasound for validation of haemarthrosis	4
Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors	4